MARC details
000 -LEADER |
fixed length control field |
03281nam a2200409 i 4500 |
001 - CONTROL NUMBER |
control field |
2015016478 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DLC |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20190729110308.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
150507s2015 nyu b 001 0 eng |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
LC control number |
2015016478 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9780199362585 (hardback) |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
DLC |
Language of cataloging |
eng |
Description conventions |
rda |
Transcribing agency |
DLC |
Modifying agency |
MvI |
042 ## - AUTHENTICATION CODE |
Authentication code |
pcc |
050 00 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RS420 |
Item number |
.L535 2015 |
084 ## - OTHER CLASSIFICATION NUMBER |
Classification number |
MED071000 |
-- |
SCI013060 |
Number source |
bisacsh |
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
615.1 |
Edition number |
23 |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal name |
Li, Jie Jack. |
245 10 - TITLE STATEMENT |
Title |
Top drugs : |
Remainder of title |
history, pharmacology, syntheses / |
Statement of responsibility, etc. |
Jie Jack Li. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
New York, NY : |
Name of producer, publisher, distributor, manufacturer |
Oxford University Press, |
Date of production, publication, distribution, manufacture, or copyright notice |
2015. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
xi, 206 pages : |
Other physical details |
charts ; |
Dimensions |
25 cm |
336 ## - CONTENT TYPE |
Content type term |
text |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
unmediated |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
volume |
Source |
rdacarrier |
520 ## - SUMMARY, ETC. |
Summary, etc. |
"Drugs like Lipitor, Plavix, Taxol, and Zoloft are integral in today's medicinal world. These widely used products save lives and improve the quality of lives, playing a crucial role in everything from cholesterol management to cancer treatment. These advances in medicine were brought into existence after nuanced process of creation, featuring a wide range of chemical and pharmacological experimentation and discovery. Top Drugs: Their History, Pharmacology, and Synthesis provides an in-depth study on ten prominent drugs, outlining the chemistry behind each one's creation. Jie Jack Li, a medicinal chemist and an expert on drug discovery, offers a thorough analysis of the landscape of current drug development. The comprehensive text is divided by health issues, including cardiovascular, cancer, metabolic diseases, and infectious diseases. Each section features individual chapters on significant drugs, outlining the chemistry and history of the drug's discovery. Li begins each chapter with the product's history, providing necessary context. Li then proceeds to describe the mechanism of action, structure-activity relationship (SAR), bioavailability, metabolism, toxicology, the discovery route, and the process route. Top Drugs: Their History, Pharmacology, and Synthesis will acclimate students, scientists, and interested laypersons to the world of chemistry and drug discovery"-- |
Assigning source |
Provided by publisher. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
"A thorough examination of the chemistry and history of ten prominent prescription drugs"-- |
Assigning source |
Provided by publisher. |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc. note |
Includes bibliographical references and index. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Machine generated contents note: -- Table of Contents -- CARDIOVASCULAR DRUGS -- Chapter 1 Atorvastatin Calcium (Lipitor) -- Chapter 2 Clopidogrel (Plavix) -- Chapter 3 Amlodipine (Novasc) -- CANCER DRUGS -- Chapter 4 Paclitaxel (Taxol) -- Chapter 5 Imatinib (Gleevec) -- DRUGS FOR METABOLIC DISEASES -- Chapter 6 Sitagliptin (Januvia) -- CNS DRUGS -- Chapter 7 Sertraline (Cymbalta) -- Chapter 8 Olanzapine (Zyprexa) -- DRUGS TO TREAT INFECTIOUS DISEASES -- Chapter 9 Sofosbuvir (Sovaldi) -- ULCER DRUGS -- Chapter 10 Esomeprazole (Nexium). |
596 ## - |
-- |
1 |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Drugs |
General subdivision |
History. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Drugs |
General subdivision |
Design. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Pharmaceutical chemistry. |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
MEDICAL / Pharmacology. |
Source of heading or term |
bisacsh |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
SCIENCE / Chemistry / Industrial & Technical. |
Source of heading or term |
bisacsh |
948 ## - LOCAL PROCESSING INFORMATION (OCLC); SERIES PART DESIGNATOR (RLIN) |
Series part designator, SPT (RLIN) |
u604248 |
949 ## - LOCAL PROCESSING INFORMATION (OCLC) |
a |
RS420 .L535 2015 |
w |
LC |
c |
1 |
h |
EY8Z |
i |
33039001361665 |
903 ## - LOCAL DATA ELEMENT C, LDC (RLIN) |
a |
32397 |